Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis

[1] Nolasco F(1986)Adult-onset minimal change nephrotic syndrome: a long-term follow-up Kidney Int 29 1215-1223

[2] Cameron JS(2007)Adult minimal-change disease: clinical characteristics, treatment, and outcomes Clin J Am Soc Nephrol 2 445-453

[3] Heywood EF(2004)Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants J Am Soc Nephrol 15 2169-2177

[4] Hicks J(2005)Focal and segmental glomerulosclerosis: definition and relevance of a partial remission J Am Soc Nephrol 16 1061-1068

[5] Ogg C(2013)Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome Pediatr Nephrol (Berlin, Germany) 28 257-264

[6] Williams DG(2012)Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome Nephrol Dial Transplant 27 1910-1915

[7] Waldman M(2010)Rituximab in refractory nephrotic syndrome Pediatr Nephrol (Berlin, Germany) 25 461-468

[8] Crew RJ(2014)Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review Am J Nephrol 39 322-330

[9] Valeri A(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 867-872

[10] Busch J(1991)Publication bias in clinical research Lancet 337 557-560

[1] Nolasco F(1986)Adult-onset minimal change nephrotic syndrome: a long-term follow-up Kidney Int 29 1215-1223

[2] Cameron JS(2007)Adult minimal-change disease: clinical characteristics, treatment, and outcomes Clin J Am Soc Nephrol 2 445-453

[3] Heywood EF(2004)Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants J Am Soc Nephrol 15 2169-2177

[4] Hicks J(2005)Focal and segmental glomerulosclerosis: definition and relevance of a partial remission J Am Soc Nephrol 16 1061-1068

[5] Ogg C(2013)Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome Pediatr Nephrol (Berlin, Germany) 28 257-264

[6] Williams DG(2012)Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome Nephrol Dial Transplant 27 1910-1915

[7] Waldman M(2010)Rituximab in refractory nephrotic syndrome Pediatr Nephrol (Berlin, Germany) 25 461-468

[8] Crew RJ(2014)Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review Am J Nephrol 39 322-330

[9] Valeri A(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 867-872

[10] Busch J(1991)Publication bias in clinical research Lancet 337 557-560